Oxis Intl Inc (OXIS) 0.0168 $OXIS
Oxis Biotech Inc. Announces Appointment of Dr. Stephen M. Chang to Scientific Advisory Board
Marketwired - Thu Jun 18, 8:37AM CDT
Oxis International, Inc. (OTCQB: OXIS), a biotechnology company focused on cannabinoid therapy development and commercialization, announced today Dr. Stephen M. Chang has joined the Scientific Advisory Board for its wholly owned subsidiary, Oxis Biotech, Inc.
Oxis Biotech Files U.S. Patent Application Covering p62/Sequestosome 1 Inhibitors For The Treatment Of Multiple Myeloma And Secondary Osteolytic Lesions
PR Newswire - Thu Jun 04, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] announced today it has filed a U.S. patent application covering additional analogs of the company's lead compound, OXS-4235, a potent p62/Sequestosome 1 (p62) inhibitor. These novel p62 inhibitors demonstrate inhibition of multiple myeloma cell growth without toxicity to normal bone marrow stromal cells. Bone marrow stromal cells are involved in hematopoiesis and certain inflammatory processes.
Millennium Healthcare Inc. Appoints Anthony Cataldo, CEO of Oxis Biotech, to Board of Advisors
Marketwired - Wed Jun 03, 11:30AM CDT
Millennium Healthcare Inc. (OTCQB: MHCC), a healthcare services and medical device distribution company, today announced that the Company has appointed Anthony (Tony) Cataldo to the Board of Advisors effective June 1, 2015.
Cannabis Stocks On The Rise In 2015
ACCESSWIRE - Thu May 14, 10:10AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 14, 2015 / Cannabis stocks have rallied in 2015 thus far. With more and more states jumping on board the marijuana legalization train, companies are now trying to take advantage of this rapidly growing space. For instance, companies that are biotech/cannabis focused companies like Oxis International (OTCQB: OXIS), security surveillance for dispensaries like Blue Line Protection Group (PINKSHEETS: BLPG), or hemp infused Beverage Companies like Totally Hemp Crazy Inc (PINKSHEETS: THCZ) have found their place in the MJ space in 2015.
OXIS Biotech Retains The Emmes Group To Assist With Its Strategic Business And Therapeutic Development Initiatives
PR Newswire - Tue May 12, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] announced today that it has retained the Emmes Group to assist with the development and execution of the Company's business, partnership, and technology licensing initiatives and strategies.
How High Have Cannabis Stocks Been This Year And Where Do You Stand?
ACCESSWIRE - Fri May 08, 11:10AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 8, 2015 / Interest in cannabis companies has continued to grow in 2015 as more states have begun to implement legalization efforts; these including options for both medical and recreational use. After more states like Texas have put wheels in motion for legalization efforts, more attention has begun to build and the 2015 market for cannabis stocks has started to look much different than the uncertainty that was seen last year. Companies like Oxis International (OTCQB: OXIS), Pazoo, Inc. (PINKSHEETS: PZOO), and Totally Hemp Crazy Inc (PINKSHEETS: THCZ) have all seen record 6-month highs this year as a flood of positive news and a more informed investment community have bolstered movement within the market.
The "Tech" Behind Biotechnology Has Evolved; 2015 Marks New Milestones
ACCESSWIRE - Thu May 07, 10:01AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 7, 2015 / The biotechnology industry has come a long way from where it was even 10 years ago. New findings, developments, and enacted regulations have given rise to programs only once dreamed of. Nearly half of America is behind the legalization of cannabis; many in favor of medical use and other novel therapies to treat the effects of cancer. Companies like Oxis International, Inc. (OTCQB: OXIS), PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), and PharmaCyte Biotech, Inc. (OTCQB: PMCB) have all begun the push for brining certain therapies to market.
PTBI: 6.61 (+0.08)
Will These Cannabis Stocks Be On Your Watchlist For May?
ACCESSWIRE - Tue May 05, 1:14PM CDT
CORAL GABLES, FL / ACCESSWIRE / May 5, 2015 / Marijuana stocks have made a serious comeback since the start of the New Year. With the hit taken by cannabis companies in 2014 it has attracted investors to invest in oversold cannabis plays. Now it's 2015 and with 23 states including the District of Columbia jumping on the marijuana legislation train, companies are finding new innovative ways to become part of the cannabis industry. For example, biotech/cannabis focused companies like Oxis International (OTCQB: OXIS), Hemp infused beverage wholesalers like Totally Hemp Crazy Inc. (PINKSHEETS: THCZ) and even extensive security & protection services like Blue Line Protection Group (PINKSHEETS: BLPG) have all found their niche in the industry.
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part VIII
Anthony Cataldo - at Seeking Alpha - Mon Apr 20, 7:25AM CDT
QAI: 29.48 (+0.11)
How Will The Cannabis Industry Look In 2015?
ACCESSWIRE - Thu Apr 16, 7:53AM CDT
CORAL GABLES, FL / ACCESSWIRE / April 16, 2015 / Cannabis stocks are in turnaround. After new states recently legalized cannabis for recreational use and many other states for medicinal use. The bottom line is Cannabis is showing progress, and this could lead to more money to make as an investor. After seeing the numbers from last year both from a revenue standpoint and a tax generation focus, many more individuals, businesses, and investors are becoming more educated on the subject. There have even been new state and federal initiatives put in motion to further open the market throughout the US.
Oxis Biotech Inc. Announces Resumption of Trading of Common Stock on Euronext Paris
PR Newswire - Fri Apr 10, 6:30AM CDT
Oxis International, Inc. (OXIS) (OXI.PA), a biotechnology company focused on cancer therapy development and commercialization, announced today that trading in its common stock will resume on Euronext Paris on April 14, 2015. Upon resumption of trading, the shares will trade in a double call auction trading mode (fixing) rather than the continuous trading mode formerly applicable to Oxis shares.
Oxis Biotech Discusses Its Immunotherapeutic Development Strategy
PR Newswire - Wed Apr 01, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] discussed during its March 31, 2015 conference call with shareholders, analysts and other interested parties certain aspects of its immunotherapeutic development strategy. During the teleconference, Anthony J. Cataldo, Chairman and Chief Executive Officer stated that Oxis Biotech is focused on developing immunotherapies for the treatment of triple-negative breast cancer, and multiple myeloma and associated osteolytic lesions which are significant unmet medical needs.
Oxis International Inc. Announces Request for Euronext Trading Suspension
PR Newswire - Tue Mar 31, 8:07AM CDT
Oxis International, Inc. (OXIS) (OXI.PA) a biotechnology company focused on biotech cancer therapy development and commercialization, announced today Oxis CEO Tony Cataldo has requested a suspension of the trading of Oxis common shares on the Euronext exchange. Oxis shares will continue to trade on the OTCQB under the symbol OXIS.
MarijuanaStocks.com to Host Oxis International (OXIS) Conference Call with CEO Tony Cataldo
ACCESSWIRE - Mon Mar 30, 11:38AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 30, 2015 / MarijuanaStocks.com-Oxis International (OTCQB: OXIS) recently announced that the Company will be holding an investor conference call on Tuesday, March 31, 2015 at 4:15pm EST to discuss recent corporate developments. As a result of receiving emails and social media messages from our loyal followers as to who will be hosting the conference call and how attendees can ask specific questions, MatrijuanaStocks.com reached out to OXIS CEO Tony Cataldo and expressed the amount of interest our followers have in the upcoming conference call.
Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh
PR Newswire - Thu Mar 26, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today the execution of an exclusive option agreement with the University of Pittsburgh related to certain patents/intellectual properties developed by Dr. Xiang-Qun Xie, Associate Dean for Research Innovation and Professor, Pharmaceutical Sciences, School of Pharmacy. These patents/intellectual properties relate to novel compositions-of-matter which could prove useful as therapeutics for the treatment of various human diseases. The term of the exclusive option is eighteen (18) months. During the term of exclusivity, the University of Pittsburgh will not offer third parties the opportunity to license these intellectual properties.
Biotechnology And The Road To Innovation: What Companies Are Pushing New Innovation In Today's Market?
ACCESSWIRE - Thu Mar 19, 8:15AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 19, 2015 / Globally, the market for biotechnology has been growing at a rate of over 10% annually according to a report from IBISWorld. Annual revenue is on the cusp of breaking $290 Billion and has many sub sectors contributing to its further expansion. Industry firms have thrived as technological advances have facilitated new discoveries and ignited higher demand from firms in the pharmaceuticals and agricultural sectors. According to the report, industry growth is forecast to continue "skyrocketing in the next five-year period" where investment in biotechnology from around the world increases, particularly from emerging economies.
Rapidly Rising: Fastfunds Financial Corporation (OTCBB:FFFC)
ACCESSWIRE - Tue Mar 17, 11:55PM CDT
WINDSOR, ON / ACCESSWIRE / March 18, 2015 / The Cannabis Capitalist, an Investment newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known stocks in the new recreational and medical Cannabis industry, would like to announce a new Company which is creating excitement on Wall Street: Fastfunds Financial (OTCBB:FFFC).
CARA: 13.28 (+0.52), GWPH: 125.86 (+5.39)
MultiCell inks R&D agreement with Oxis Biotech
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 12:10PM CDT
Oxis Biotech Licenses Rights To Antibody-Drug Conjugates For The Treatment Of Cancer
PR Newswire - Thu Mar 12, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. (MCIT) concerning the development of certain antibody-drug conjugates (ADCs). These ADCs are thought to be useful for the treatment of triple-negative breast cancer, and multiple myeloma and associated osteolytic lesions which are significant unmet medical needs.
Oxis Biotech Inc. Announces Appointment of Dr. Stephen M. Chang to Scientific Advisory Board
Marketwired - Thu Jun 18, 8:37AM CDT
Oxis International, Inc. (OTCQB: OXIS), a biotechnology company focused on cannabinoid therapy development and commercialization, announced today Dr. Stephen M. Chang has joined the Scientific Advisory Board for its wholly owned subsidiary, Oxis Biotech, Inc.
Oxis Biotech Files U.S. Patent Application Covering p62/Sequestosome 1 Inhibitors For The Treatment Of Multiple Myeloma And Secondary Osteolytic Lesions
PR Newswire - Thu Jun 04, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] announced today it has filed a U.S. patent application covering additional analogs of the company's lead compound, OXS-4235, a potent p62/Sequestosome 1 (p62) inhibitor. These novel p62 inhibitors demonstrate inhibition of multiple myeloma cell growth without toxicity to normal bone marrow stromal cells. Bone marrow stromal cells are involved in hematopoiesis and certain inflammatory processes.
Millennium Healthcare Inc. Appoints Anthony Cataldo, CEO of Oxis Biotech, to Board of Advisors
Marketwired - Wed Jun 03, 11:30AM CDT
Millennium Healthcare Inc. (OTCQB: MHCC), a healthcare services and medical device distribution company, today announced that the Company has appointed Anthony (Tony) Cataldo to the Board of Advisors effective June 1, 2015.
Cannabis Stocks On The Rise In 2015
ACCESSWIRE - Thu May 14, 10:10AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 14, 2015 / Cannabis stocks have rallied in 2015 thus far. With more and more states jumping on board the marijuana legalization train, companies are now trying to take advantage of this rapidly growing space. For instance, companies that are biotech/cannabis focused companies like Oxis International (OTCQB: OXIS), security surveillance for dispensaries like Blue Line Protection Group (PINKSHEETS: BLPG), or hemp infused Beverage Companies like Totally Hemp Crazy Inc (PINKSHEETS: THCZ) have found their place in the MJ space in 2015.
OXIS Biotech Retains The Emmes Group To Assist With Its Strategic Business And Therapeutic Development Initiatives
PR Newswire - Tue May 12, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] announced today that it has retained the Emmes Group to assist with the development and execution of the Company's business, partnership, and technology licensing initiatives and strategies.
How High Have Cannabis Stocks Been This Year And Where Do You Stand?
ACCESSWIRE - Fri May 08, 11:10AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 8, 2015 / Interest in cannabis companies has continued to grow in 2015 as more states have begun to implement legalization efforts; these including options for both medical and recreational use. After more states like Texas have put wheels in motion for legalization efforts, more attention has begun to build and the 2015 market for cannabis stocks has started to look much different than the uncertainty that was seen last year. Companies like Oxis International (OTCQB: OXIS), Pazoo, Inc. (PINKSHEETS: PZOO), and Totally Hemp Crazy Inc (PINKSHEETS: THCZ) have all seen record 6-month highs this year as a flood of positive news and a more informed investment community have bolstered movement within the market.
The "Tech" Behind Biotechnology Has Evolved; 2015 Marks New Milestones
ACCESSWIRE - Thu May 07, 10:01AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 7, 2015 / The biotechnology industry has come a long way from where it was even 10 years ago. New findings, developments, and enacted regulations have given rise to programs only once dreamed of. Nearly half of America is behind the legalization of cannabis; many in favor of medical use and other novel therapies to treat the effects of cancer. Companies like Oxis International, Inc. (OTCQB: OXIS), PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), and PharmaCyte Biotech, Inc. (OTCQB: PMCB) have all begun the push for brining certain therapies to market.
PTBI: 6.61 (+0.08)
Will These Cannabis Stocks Be On Your Watchlist For May?
ACCESSWIRE - Tue May 05, 1:14PM CDT
CORAL GABLES, FL / ACCESSWIRE / May 5, 2015 / Marijuana stocks have made a serious comeback since the start of the New Year. With the hit taken by cannabis companies in 2014 it has attracted investors to invest in oversold cannabis plays. Now it's 2015 and with 23 states including the District of Columbia jumping on the marijuana legislation train, companies are finding new innovative ways to become part of the cannabis industry. For example, biotech/cannabis focused companies like Oxis International (OTCQB: OXIS), Hemp infused beverage wholesalers like Totally Hemp Crazy Inc. (PINKSHEETS: THCZ) and even extensive security & protection services like Blue Line Protection Group (PINKSHEETS: BLPG) have all found their niche in the industry.
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part VIII
Anthony Cataldo - at Seeking Alpha - Mon Apr 20, 7:25AM CDT
QAI: 29.48 (+0.11)
How Will The Cannabis Industry Look In 2015?
ACCESSWIRE - Thu Apr 16, 7:53AM CDT
CORAL GABLES, FL / ACCESSWIRE / April 16, 2015 / Cannabis stocks are in turnaround. After new states recently legalized cannabis for recreational use and many other states for medicinal use. The bottom line is Cannabis is showing progress, and this could lead to more money to make as an investor. After seeing the numbers from last year both from a revenue standpoint and a tax generation focus, many more individuals, businesses, and investors are becoming more educated on the subject. There have even been new state and federal initiatives put in motion to further open the market throughout the US.
Oxis Biotech Inc. Announces Resumption of Trading of Common Stock on Euronext Paris
PR Newswire - Fri Apr 10, 6:30AM CDT
Oxis International, Inc. (OXIS) (OXI.PA), a biotechnology company focused on cancer therapy development and commercialization, announced today that trading in its common stock will resume on Euronext Paris on April 14, 2015. Upon resumption of trading, the shares will trade in a double call auction trading mode (fixing) rather than the continuous trading mode formerly applicable to Oxis shares.
Oxis Biotech Discusses Its Immunotherapeutic Development Strategy
PR Newswire - Wed Apr 01, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] discussed during its March 31, 2015 conference call with shareholders, analysts and other interested parties certain aspects of its immunotherapeutic development strategy. During the teleconference, Anthony J. Cataldo, Chairman and Chief Executive Officer stated that Oxis Biotech is focused on developing immunotherapies for the treatment of triple-negative breast cancer, and multiple myeloma and associated osteolytic lesions which are significant unmet medical needs.
Oxis International Inc. Announces Request for Euronext Trading Suspension
PR Newswire - Tue Mar 31, 8:07AM CDT
Oxis International, Inc. (OXIS) (OXI.PA) a biotechnology company focused on biotech cancer therapy development and commercialization, announced today Oxis CEO Tony Cataldo has requested a suspension of the trading of Oxis common shares on the Euronext exchange. Oxis shares will continue to trade on the OTCQB under the symbol OXIS.
MarijuanaStocks.com to Host Oxis International (OXIS) Conference Call with CEO Tony Cataldo
ACCESSWIRE - Mon Mar 30, 11:38AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 30, 2015 / MarijuanaStocks.com-Oxis International (OTCQB: OXIS) recently announced that the Company will be holding an investor conference call on Tuesday, March 31, 2015 at 4:15pm EST to discuss recent corporate developments. As a result of receiving emails and social media messages from our loyal followers as to who will be hosting the conference call and how attendees can ask specific questions, MatrijuanaStocks.com reached out to OXIS CEO Tony Cataldo and expressed the amount of interest our followers have in the upcoming conference call.
Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh
PR Newswire - Thu Mar 26, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today the execution of an exclusive option agreement with the University of Pittsburgh related to certain patents/intellectual properties developed by Dr. Xiang-Qun Xie, Associate Dean for Research Innovation and Professor, Pharmaceutical Sciences, School of Pharmacy. These patents/intellectual properties relate to novel compositions-of-matter which could prove useful as therapeutics for the treatment of various human diseases. The term of the exclusive option is eighteen (18) months. During the term of exclusivity, the University of Pittsburgh will not offer third parties the opportunity to license these intellectual properties.
Biotechnology And The Road To Innovation: What Companies Are Pushing New Innovation In Today's Market?
ACCESSWIRE - Thu Mar 19, 8:15AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 19, 2015 / Globally, the market for biotechnology has been growing at a rate of over 10% annually according to a report from IBISWorld. Annual revenue is on the cusp of breaking $290 Billion and has many sub sectors contributing to its further expansion. Industry firms have thrived as technological advances have facilitated new discoveries and ignited higher demand from firms in the pharmaceuticals and agricultural sectors. According to the report, industry growth is forecast to continue "skyrocketing in the next five-year period" where investment in biotechnology from around the world increases, particularly from emerging economies.
Rapidly Rising: Fastfunds Financial Corporation (OTCBB:FFFC)
ACCESSWIRE - Tue Mar 17, 11:55PM CDT
WINDSOR, ON / ACCESSWIRE / March 18, 2015 / The Cannabis Capitalist, an Investment newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known stocks in the new recreational and medical Cannabis industry, would like to announce a new Company which is creating excitement on Wall Street: Fastfunds Financial (OTCBB:FFFC).
CARA: 13.28 (+0.52), GWPH: 125.86 (+5.39)
MultiCell inks R&D agreement with Oxis Biotech
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 12:10PM CDT
Oxis Biotech Licenses Rights To Antibody-Drug Conjugates For The Treatment Of Cancer
PR Newswire - Thu Mar 12, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. (MCIT) concerning the development of certain antibody-drug conjugates (ADCs). These ADCs are thought to be useful for the treatment of triple-negative breast cancer, and multiple myeloma and associated osteolytic lesions which are significant unmet medical needs.
